The addition of bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), to platinum-based chemotherapy resulted in an improved response and survival in patients with non-small cell lung cancer. Here, VEGFA is linked to non-small cell lung carcinoma.